News & Updates

Patients with metastatic prostate cancer can safely engage in intense exercise training to improve survival outcomes, suggests a study presented at AACR 2024.

Several patients with metastatic castration-resistant prostate cancer (mCRPC) discontinue the use of androgen receptor‒targeted therapies (ARTs) because of disease progression, while a few stopped ARTs due to treatment toxicity, according to a study.

Transurethral water vapour thermal therapy (WVTT) delivered in an office-based setting under local anaesthesia alone is an effective and safe alternative for surgical treatment of benign prostatic hyperplasia (BPH) in Chinese patients, researchers from the Chinese University of Hong Kong (CUHK) have reported.

Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide reported more fatigue, depression and deterioration in perceived cognitive ability, and slower reaction time than those receiving abiraterone acetate, according to results of the ACE study.

Neoadjuvant chemohormonal therapy (NCHT) plus radical prostatectomy (RP) confers significant biochemical progression-free survival (bPFS) benefits relative to neoadjuvant hormonal therapy (NHT) plus RP on patients with high-risk, locally advanced prostate cancer, reports a study.